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Triple-negative breast cancer (TNBC) accounts for 20% of breast
cancer in women and lacks an effective targeted therapy. There-
fore, finding common vulnerabilities in these tumors represents an
opportunity for more effective treatment. Despite the growing
appreciation of G-protein–coupled receptor (GPCR)-mediated sig-
naling in cancer pathogenesis, very little is known about the role
GPCRs play in TNBC. Using genomic information of human breast
cancer, we have discovered that the orphan GPCR, G-protein–coupled
receptor 161 (GPR161) is overexpressed specifically in TNBC and
correlates with poor prognosis. Knockdown of GPR161 impairs pro-
liferation of human basal breast cancer cell lines. Overexpression of
GPR161 in human mammary epithelial cells increases cell prolifera-
tion, migration, intracellular accumulation of E-cadherin, and for-
mation of multiacinar structures in 3D culture. GPR161 forms a
signaling complex with the scaffold proteins β-arrestin 2 and Ile Gln
motif containing GTPase Activating Protein 1, a regulator of mam-
malian target of rapamycin complex 1 and E-cadherin. Consistently,
GPR161 amplified breast tumors and cells overexpressing GPR161
activate mammalian target of rapamycin signaling and decrease Ile
Gln motif containing GTPase Activating Protein 1 phosphorylation.
Thus, we identify the orphan GPCR, GPR161, as an important reg-
ulator and a potential drug target for TNBC.
G-protein–coupled receptors (GPCRs) are heptahelical mem-brane proteins responsible for transducing signals from a di-
verse range of ligands to affect numerous physiological processes,
including vision, olfaction, behavior, and autonomic nervous sys-
tem transmission (1). These properties have allowed the wide-
spread development of GPCR-targeted drugs, which represent
nearly 30% of all currently used therapeutics, for indications
ranging from allergy to depression to hypertension. However, the
clinical utility of targeting GPCRs in cancer therapy remains poorly
defined (2, 3). GPCRs regulate many aspects of tumorigenesis,
including proliferation, invasion, survival at the secondary site, and
immune cell function, as well as several cancer-associated signaling
pathways (4). Emerging large-scale genomic analyses have recently
provided further evidence of frequent GPCR alterations in human
tumors (5–10). For example, 20% of all human tumors sequenced
contain mutations in GPCRs; the phenotypic outcome of these
mutations remains unknown and thus provides a wealth of infor-
mation for the development of hypothesis-driven experiments (5).
In addition to mutations, alterations in gene expression, copy
number, and promoter methylation of GPCRs have been detected.
Determining the contribution of such alterations to cancer initia-
tion and progression remains a significant challenge yet critical
both for discovery of driver oncogenes and for the development of
targeted therapeutics.
Triple-negative breast cancer (TNBC), characterized by lack
of expression of estrogen receptor (ER), progesterone receptor
(PR), and epidermal growth factor receptor 2 (HER2), is asso-
ciated with early recurrence and poor outcome (11). Mutations
in BRCA1 and BRCA2 account for 15% of TNBC, and several
other susceptibility loci have been identified (12). Representing
nearly a quarter of all breast cancers, TNBC lacks an effective
targeted therapy due to high levels of genetic heterogeneity.
Therefore, finding common druggable targets is a critical en-
deavor. We used large-scale genomic analysis to discover GPCRs
up-regulated in TNBC. This method uncovered the poorly
characterized class A rhodopsin family orphan GPCR, GPR161.
Several studies have identified an important role for GPR161
during normal development. An 8 bp mutation in GPR161,
resulting in a premature stop codon and truncated C terminus,
was identified as the cause of the vacuolated lens spontaneous
mouse model, exhibiting neural tube defects and congenital
cataracts (13). Consistent with these phenotypes, GPR161 is
expressed in the lateral neural folds and in the developing lens
(13). Knockdown of GPR161 in the zebrafish embryo disrupts
left–right patterning in the lateral plate mesoderm through
modulation of Ca2+ levels, resulting in aberrant cardiac mor-
phogenesis (14). Recently, GPR161 was shown to localize to
primary cilia and regulate Sonic hedgehog (Shh) signaling (15).
Expression of GPR161 inhibits Shh through Gαs-induced cyclic
adenosine monophosphate (cAMP) accumulation, resulting in
protein kinase A–mediated processing of Gli3 (15). In addition,
GPR161 is part of a signaling network that confers resistance to
MAP kinase pathway inhibition in melanoma (16).
We describe a role for GPR161 in the pathogenesis of human
TNBC. We provide evidence that GPR161 promotes pro-
liferation through activation of mammalian target of rapamycin
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complex 1 (mTORC1), stimulates migration and invasion, and
disrupts E-cadherin (E-cad) localization. We also identify a pro-
tein complex consisting of GPR161 and the scaffold proteins
β-arrestin 2 (βArr2) and IQ motif containing GTPase Activating
Protein 1 (IQGAP1), and demonstrate that GPR161 induces pro-
liferation and migration in an IQGAP1-dependent manner. We
identify GPR161 as a promoter of cancer cell proliferation and
migration and as a promising drug target in TNBC.
Results
GPR161 Is Overexpressed in TNBC. The lack of common genetic
alterations in TNBC has hampered the development of targeted
therapies. To identify potential targets, we used the large-scale
analyses of patient tumor samples from The Cancer Genome
Atlas (TCGA) to identify GPCR specifically up-regulated in
TNBC. GPCRs were selected for this analysis for their amena-
bility to inhibition by small molecules, peptides, and antibodies
and their regulation of several cancer-associated signaling path-
ways. We determined the reads per kilobase per million reads
(RPKM) of 366 nonsensory GPCRs from RNAseq data generated
by TCGA. Forty-five GPCRs were significantly overexpressed
(greater than twofold) in TNBC compared with unmatched nor-
mal breast tissue. We chose to first investigate the biological
function of GPR161 due to the limited current knowledge about
its role in cancer. We found that GPR161 was up-regulated 2.2-
fold in TNBC versus unmatched normal breast tissue (Fig. 1A).
We extended this analysis to other breast cancer subtypes, in-
cluding the ER-positive Luminal A and B (LumA/B), as well as
HER2-positive tumors (Fig. 1A). Although there was no change in
GPR161 expression in HER2-positive tumors, GPR161 expres-
sion decreased significantly in LumA (0.683-fold change from
control, P < 1 × 10−10) and LumB (0.781-fold change from con-
trol, P < 2.22 × 10−5). This correlation was consistent in the
Richardson Breast 2 panel, with GPR161 showing a 2.1-fold in-
crease in ductal breast cancer compared with normal breast (Fig.
S1A), and the Farmer Breast study, with GPR161 showing a 2.3-
fold increase in basal-like invasive breast cancer (IBC) versus
luminal-like IBC (Fig. S1B). Therefore, GPR161 was specifically
overexpressed in human TNBC.
High Expression of GPR161 Correlates with Relapse in Human TNBC.
To determine the clinical relevance of GPR161 expression, we
compared relapse-free survival rates for breast cancer patients
within the highest or lowest quartiles of GPR161 expression (Fig.
S1C and Fig. 1 B and C). Among basal breast cancer patients with
lymph-node–positive disease, high GPR161 expression decreased
time to relapse by 113% (hazard ratio, HR = 2.13) (Fig. 1B). Time
to relapse decreased 54% when all basal breast cancers were an-
alyzed (HR = 1.54) (Fig. 1C). Finally, for patients with any type of
breast cancer, high GPR161 expression was correlated with a 27%
decrease in time to relapse (HR = 1.27) (Fig. S1C). Therefore,
GPR161 was overexpressed in basal breast cancer and had
prognostic value.
GPR161 Is Expressed in Basal/Myoepithelial Cells in Normal and
Cancer Cells. To determine the normal expression pattern of
GPR161 in the human mammary gland, we costained breast
tissue with antibodies specific for GPR161 and the luminal epi-
thelial marker E-cad (Fig. 1 D and E, i). GPR161 expression was
detected solely in the myoepithelium, and not in the E-cad–
positive luminal epithelial cells that surround the luminal space.
To extend our gene expression analysis of GPR161 in breast
cancer to the protein level, we performed immunohistochemical
analysis of GPR161 and E-cad in a human breast cancer tissue
array. In early stage disease (ductal carcinoma in situ, DCIS),
there was no change detected in the GPR161-positive pop-
ulation, whereas the E-cad–positive population increased in
number (Fig. 1 E, ii). Among the 20 ER+ invasive ductal car-
cinoma (IDC) tumors analyzed, 19 showed strong E-cad staining,
with only one staining positive for GPR161 (Fig. 1 E, iii). In
contrast, four out of six triple-negative IDC tumor samples
stained strongly for GPR161 (Fig. 1 E, iv). Consistent with these
observations, GPR161 protein levels were higher in three triple-
negative cell lines (BT-20, MDA-MB-157, and MDA-MB-436)
than two luminal-like cell lines (BT-474 and MDA-MB-361) (Fig.
1F). Taken together, these results demonstrate that GPR161 was
overexpressed in human TNBC and TNBC cell lines.
GPR161 Induces Multiacinar Formation in 3D Culture. To begin to
understand the biological relevance of GPR161 overexpression,
we generated MCF-10A cells overexpressing GPR161 (Fig. 2A).
Stable populations were selected after infection with GPR161
retrovirus and analyzed for GPR161 expression (Fig. 2A). We
chose lines with modest GPR161 overexpression, in accordance
with the 2.2-fold increase noted in human tumor samples (Fig.
1A). When grown on a 3D Matrigel layer, MCF-10A cells form
acinar structures with hollow lumens (17). Activation of onco-
genes in this context disrupts acinar morphogenesis and can re-
sult in large, disorganized multiacinar structures (17). To probe
the impact of GPR161 overexpression on acinar morphogenesis,
we grew MCF-10A cells [either murine stem cell virus-puromycin-
IRES-GFP (MSCV-PIG) or GPR161] in 3D culture for 14 d (Fig.
2B). Whereas control acini formed round, regular structures, cells
expressing GPR161 formed large, multiacinar structures (Fig. 2
B and C). Overexpression of GPR161 in MDA-MB-361 cells
grown in 3D culture similarly disrupted 3D growth (Fig. S1 D and
E). Optical sectioning through the center of the MCF-10A acini
revealed the appearance of hollow lumens in control acini (Fig.
2B, Lower Left DAPI image). In contrast, GPR161-expressing
MCF-10A acini displayed filled lumens (Fig. 2B, Lower RightDAPI
image). Quantitative analysis of acinar size showed a greater than
twofold increase in GPR161-expressing acini than controls (Fig.
2C). To determine the mechanism by which GPR161 induced
multiacinar formation and filled lumens, we analyzed proliferation
in day 14 acini (Fig. 2D). In control acini, proliferation was low and
Ki67 was rarely detected in the lumen (6.3% of acini). In con-
trast, in GPR161 acini, proliferation was maintained at day 14
and Ki67+ cells were detected in the lumens of 57.5% of the acini
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Fig. 1. GPR161 is overexpressed in TNBC. (A) GPR161 expression was ana-
lyzed in 530 LumA, 88 LumB, 32 HER2, 98 TNBC, and 100 nonmatched con-
trols. P values were calculated with a Mann–Whitney U test. (B) Kaplan–Meier
analysis of effect of GPR161 expression on relapse-free survival in basal,
lymph-node–positive breast cancer patients. P values were calculated with
a Log Rank Test. (C) Kaplan–Meier analysis of effect of GPR161 expression on
relapse-free survival in basal breast cancer patients. P values were calculated
with a log rank test. (D) Immunohistochemical (IHC) analysis of GPR161 and
E-cad in normal human mammary gland. (Scale bar, 10 μm.) (E) IHC analysis of
GPR161 and E-cad in normal human mammary gland (i), DCIS (ii), and IDC,
either ER+/PR+ (iii) or triple-negative (iv). (Scale bar, 30 μm.) (F) Expression of
GPR161 was measured by Western blot in luminal (BT-474 and MDA-MB-361)
and TNBC (BT-20, MDA-MB-157, and MDA-MB-436) cell lines.
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(see arrows in Fig. 2D). Therefore, overexpression of GPR161
induced cell proliferation and disrupted morphogenesis of mam-
mary epithelial cells grown in 3D culture.
GPR161 Regulates Proliferation in Mammary Cell Lines. To rule out
the possibility that GPR161-induced proliferation was restricted
to basal epithelial cells, we also overexpressed (less that 2.0-fold)
GPR161 in two luminal-like breast cancer cell lines (BT-474 and
MDA-MB-361) (Fig. 2A). Overexpression of GPR161 increased
proliferation of MCF-10A cells compared with cells expressing
an empty vector (MSCV-PIG) (Fig. 2E). Similarly, GPR161
overexpression increased proliferation in both MDA-MB-361
and BT-474 cells (Fig. 2E and Fig. S1F). Therefore, over-
expression of GPR161 to the levels seen in TNBC can enhance
proliferation in mammary epithelial cells and cancer-derived
luminal tumor cell lines.
To determine if GPR161 is required for proliferation of basal
breast cancer cells, we used shRNA to knock down GPR161 in
MCF-10A and MDA-MB-436 TNBC cell lines (Fig. 2F). Two
hairpins significantly reduced GPR161 expression compared
with a control shRNA in both cell lines. GPR161 knockdown had
no significant effect on proliferation of nontransformed MCF-
10A cells (Fig. 2G). However, proliferation was reduced more
than twofold in MDA-MB-436 cells, likely because the cancer
cells and not MCF-10A have developed a dependence on GPR161-
regulated pathways (Fig. 2H). Therefore, GPR161 is both necessary
and sufficient for regulating proliferation in breast cancer cells.
GPR161 Induces Cell Proliferation Through mTOR. To obtain insight
into pathways activated in tumors with high levels of GPR161,
we analyzed reverse phase protein array (RPPA) data from the
TCGA database. Tumors with high levels of GPR161 had higher
phosphorylation of mammalian target of rapamycin (mTOR)
pathway components EIF4BP1, RPS6KA1, JUN, and RB1
compared with tumors expressing lower levels of GPR161 (Fig.
3A). We investigated if GPR161 overexpression activated the
mTOR signaling pathway in cells in culture. Under normal
growth conditions, control MDA-MD-361 cells display low levels
of phosphorylation of the AKT pathway component p70S6 kinase
(p70S6K) at T389 and the downstream target, ribosomal protein
S6, at S235/236 (Fig. 3B). In contrast, cells expressing GPR161
display enhanced phospho-p70S6K and phospho-S6. A similar
pattern of S6 phosphorylation is observed in control and GPR161-
expressing BT-474 cells (Fig. S2A). mTOR activation is inhibited
by PRAS40 and phosphorylation of PRAS40 at Thr246 relieves this
inhibition (18). Therefore, we monitored PRAS40 phosphorylation
in MDA-MD-361 cells expressing an empty vector or GPR161.
Phospho-PRAS40 was markedly increased in GPR161-expressing
cells (Fig. 3B). Similarly, we detected increased mTOR phosphor-
ylation at S2448 in GPR161-expressing cells (Fig. 3B). To determine
the relevance of mTOR activation in the GPR161-induced phos-
phorylation of S6, we treated the cells with rapamycin, an mTOR
inhibitor (Fig. 3C). Although phospho-S6 levels were higher in
GPR161-expressing cells, this increase was abolished upon rapa-
mycin treatment. Therefore, GPR161-induced S6 phosphory-
lation was mTORC1-dependent. To determine the relevance of the
mTOR pathway to GPR161-induced proliferation, MDA-MB-361
cell growth was measured in the absence and presence of rapamycin
(Fig. 3D). GPR161-induced cell proliferation was inhibited in the
presence of rapamycin. Furthermore, rapamycin treatment inhibi-
ted multiacinar structure formation in GPR161-expressing MCF-
10A acini (Fig. 3 E and F). These observations suggest that GPR161
mediates cell proliferation in an mTORC1-dependent manner.
GPR161 Induces Migration and Invasion of Mammary Epithelial Cells.
When grown on standard tissue culture dishes, GPR161-expressing
cells displayed robust changes in cell shape. Subconfluent MCF-
10A and MDA-MB-361 cells formed epithelial cell colonies with
smooth, round edges (Fig. S2 B and C). In contrast, cells expressing
GPR161 formed colonies with poorly defined colony borders, with
sharp edges and protrusions (Fig. S2 B and C), suggesting migra-
tory/invasive properties. Consistent with this possibility, overex-
pression of GPR161 led to a twofold increase in the migratory
ability of MDA-MB-361 and BT-474 cells, as monitored by trans-
well migration assay over 24 h (Fig. 4A). Invasive potential was
determined by culturing GPR161-expressing MCF-10A cells in 3D
in a 1:1 mix of Matrigel and collagen. Whereas control cells formed
round, noninvasive structures, GPR161-expressing MCF-10A acini
were multiacinar and invasive (Fig. 4B). GPR161-expressing acini
also had disrupted Laminin-V staining, a hallmark of invasion in
MCF-10A culture (Fig. 4C).
GPR161 Induces Intracellular Accumulation of E-cad. The GPR161-
induced change in cell shape and invasive ability led us to in-
vestigate the possibility that the cells had undergone an epithelial-
to-mesenchymal transition. However, Western blot analysis
of protein lysates from control and GPR161-expressing MCF-
10A cells failed to show changes in the levels of the mesen-
chymal markers vimentin, snail, fibronectin, and N-cadherin
(Fig. S2D).
Close inspection of the GPR161-expressing MCF-10A acinar
structures revealed a rough surface topology, suggesting a defect
in cell–cell adhesion (Fig. 4D). Therefore, we probed the localiza-
tion of the adherens junction protein E-cad in GPR161-expressing
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Fig. 2. GPR161 overexpression induces cell proliferation. (A) Western blot
analysis of GPR161 overexpression in MCF-10A, BT-474, and MDA-MB-361
cells. (B) MCF-10A cells, either MSCV-PIG or GPR161, were grown as 3D acini
for 14 d. Phase contrast (upper panels) and DAPI staining (lower panels)
were used to monitor acinar morphology. [Scale bar, 100 μm (Upper), 75 μm
(Upper Inset), 50 μm (Lower), and 20 μm (Lower Inset).] (C) Acinar area was
measured for MSCV-PIG and GPR161 MCF-10A acini. *P < 0.05 for the dif-
ference between GPR161 cells and those expressing the empty vector using
an unpaired t test. (D) Proliferation was analyzed in MCF-10A acini by IF
staining of Ki67. Arrows denote Ki67-positive central acinar cells. [Scale bar,
50 μm and (Inset) 20 μm.] (E) MTT assay was used to measure cell pro-
liferation in the nontransformed mammary epithelial cell line MCF-10A and
the luminal cancer cell lines MDA-MB-361 and BT-474, stably expressing an
empty vector (MSCV-PIG) or GPR161. *P < 0.05 for the difference between
GPR161 cells and those expressing the empty vector using an unpaired t test.
(F) Western blot analysis of GPR161 knockdown in MCF-10A and MDA-MB-
436 cells. (G) MTT assay was used to measure cell proliferation in control or
GPR161-deficient MCF-10A cells. (H) MTT assay was used to measure cell
proliferation in control or GPR161-deficient MDA-MB-436 cells. *P < 0.05 for
the difference between cells expressing a control shRNA and those with a
GPR161 shRNA using an unpaired t test.
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cells. Total levels of E-cad were modestly reduced upon expression
of GPR161. In addition, GPR161-expressing MCF-10A cells dis-
played markedly higher levels of intracellular E-cad than control
cells as measured by immunoblot (Fig. 4E). This pattern was similar
in MDA-MB-361 cells, where E-cad was localized to the cytosol
upon GPR161 expression as detected by immunofluorescence (Fig.
4F). This observation was extended to human tumors, where four
TNBC samples expressing high levels of GPR161 displayed in-
tracellular E-cad, compared with predominantly plasma-mem-
brane–localized E-cad in six ER+/GPR161– tumors (Fig. 4G and
Fig. S2E). Therefore, GPR161 expression is associated with both
decrease in levels and redistribution of E-cad from the plasma
membrane in epithelial cells.
GPR161 Forms a Complex with IQGAP1 and βArr2. To define the
mechanism by which GPR161 induces proliferation, migration,
and invasion, we focused on an adherens junction-localized scaf-
fold protein that is related to GPCR signaling. IQGAP1 regulates
a vast array of cellular functions through interactions with proteins
such as E-cad, Neural Wiskott-Aldrich syndrome protein (N-WASP),
Cdc42, and the exocyst complex (19). IQGAP1 has been reported
to interact with βArr2, a scaffold protein that binds to activated
GPCRs and regulates signaling and receptor endocytosis (20).
IQGAP1 promotes proliferation and migration, and overexpression
has been associated with poor prog-nosis in advanced colorectal
cancer (21–23). Interestingly, IQGAP1 can coordinate cell growth
and division in a phosphorylation-dependent manner (24). Phos-
phorylation of IQGAP1 at Ser1339 by protein kinase C allows
binding of Cdc42 (25), whereas unphosphorylated IQGAP1
binds mTOR and leads to activation of downstream signals, in-
cluding phosphorylation of S6 (26, 27). To determine if GPR161
overexpression influences the phosphorylation status of IQGAP1,
we immunoprecipitated endogenous IQGAP1 from control or
GPR161-expressing MCF-10A and MDA-MB-361 cells and ana-
lyzed serine phosphorylation by immunoblot analysis (Fig. 5A). In
both cell lines, expression of GPR161 induced a striking decrease
in IQGAP1 serine phosphorylation, consistent with GPR161-in-
duced mTOR activation.
To test the possibility that GPR161 forms a signaling complex
with IQGAP1 and βArr2, we immunoprecipated myc-tagged
IQGAP1 from 293T cell lysates coexpressing FLAG-tagged
GPR161 (Fig. 5B). Myc-IQGAP1 was able to pull down FLAG-
GPR161. Immunoprecipitation (IP) of βArr1 failed to pull down
either myc-IQGAP1 or FLAG-GPR161 (Fig. 5C, center lane). In
contrast, IP of βArr2 pulled down both myc-IQGAP1 and
FLAG-GPR161 (Fig. 5C, right lane) in cells coexpressing
FLAG-GPR161, myc-IQGAP1 with either HA-tagged βArr1
or βArr2. Furthermore, IP of endogenous GPR161 immunopreci-
pitated both IQGAP1 and βArr2, and IQGAP1 immunoprecipi-
tated GPR161 and βArr2 (Fig. 5D). Although these results do not
prove the existence of a trimeric complex, they suggest that βArr2
may serve as a scaffold connecting GPR161 and IQGAP1.
To determine the requirement for IQGAP1 in GPR161-
induced proliferation and migration, we used siRNA to knock
down IQGAP1 in MDA-MB-361 cells (Fig. 5E). Knockdown of
IQGAP1 attenuated both GPR161-induced proliferation (Fig. 5F)
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and transwell migration (Fig. 5G). Therefore, GPR161 pro-
motes cell proliferation and cell migrations in an IQGAP1-
dependent manner.
GPR161 and IQGAP1 Are Coamplified in Human Breast Cancer. As
both GPR161 (this study) and IQGAP1 (28) have been impli-
cated in human breast cancer pathogenesis, we sought to in-
vestigate the cooccurrence of alterations in these two genes. Of
the 748 tumors analyzed from the TCGA, 166 (22.2%) contained
amplification of GPR161 and 39 (5.2%) contained amplification
of IQGAP1 (Fig. 5H). Thirteen tumors contained alterations in
both genes, a statistically significant outcome (P < 0.036) com-
pared with that expected from random overlap. Despite the signif-
icant association observed in all breast cancers, TNBC represented
a small subset and hence did not reach statistical significance.
Therefore, there is likely a selection for coamplification of GPR161
and IQGAP1 during breast cancer progression.
Discussion
Taken together, our results identify GPR161 as a prognostic
biomarker for TNBC and demonstrate that GPR161 is an im-
portant regulator of cell proliferation and migration in breast
cancer cells. We identify activation of mTORC1/S6K as an ef-
fector pathway and identify IQGAP1 and βArr2 as GPR161
binding partners. In addition, we uncover genetic interactions be-
tween GPR161 and IQGAP1 in human breast cancer.
Phosphorylation of the scaffold protein IQGAP1 has recently
been recognized as a regulator of nutrient and growth factor
signaling (24). Phosphorylation of IQGAP1 at Ser1443 allows
binding of CDC42, whereas unphosphorylated IQGAP1 promotes
activation of mTOR. We find that overexpression of GPR161 de-
creases IQGAP1 serine phosphorylation, consistent with the ob-
served activation of mTORC1. Whether GPR161 reduces the
activity of PKC (the IQGAP1 Ser1443 kinase), or activates an un-
known phosphatase, remains to be determined.
Genomic analyses of human tumors have uncovered widespread
alterations in GPCRs in numerous cancer types (5, 29). However,
the contribution of these alterations to human tumorigenesis
remains unknown. Our study used genomic information to identify
GPR161 as a regulator of mammary epithelial cell proliferation
and invasion, and a putative drug target, in TNBC. We also
identified two breast cancer GPR161 mutations in the Catalog of
Somatic Mutations in Cancer database. One mutation (R91G) is
found within the first extracellular loop and may therefore play
a role in ligand binding. The other, S251G, is within the third
intracellular loop, a region known to be phosphorylated in re-
sponse to activation of many GPCRs and the site of interaction of
β-arrestins. The importance of these mutations in cancer remains to
be investigated. However, we demonstrate that expression of
GPR161 is prognostic, suggesting a role forGPR161 in determining
patient outcomes. Interestingly, TCGA data across multiple cancer
types uncover recurrent amplifications of GPR161 in bladder uro-
thelial carcinoma, lung adenocarcinoma, and melanoma. It is likely
that developing ways to target GPR161 may have implications be-
yond breast cancer.
Materials and Methods
Plasmids and Antibodies. The GPR161 cDNA was obtained from Origene and
cloned into the MSCV-PIG retroviral vector. Expression vectors containing
myc-IQGAP1, HA-βArr1, and HA-βArr2 were obtained from Addgene. Anti-
bodies were obtained from the following sources: GPR161 (Abcam), E-cad
(BD Biosciences), Actin (Sigma), Ki67 (Invitrogen), phospho-p70S6K (Cell
Signaling), p70S6K (Cell Signaling), phospho-S6 (Cell Signaling), S6 (Cell
Signaling), phospho-mTOR (Cell Signaling), mTOR (Cell Signaling), Laminin V
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Fig. 4. GPR161 induces migration and invasion of mammary epithelial cells.
(A) Quantification of transwell migration assay of MDA-MB-361 and BT-474
cells either stably expressing an empty vector (MSCV-PIG) or GPR161. *P <
0.05 using an unpaired t test. (B) MCF-10A cells, either MSCV-PIG or GPR161,
were grown as 3D acini in 1:1 Matrigel/collagen for 14 d. Phase contrast was
used to monitor acinar morphology. (Scale bar, 20 μm.) (C) Invasion was
analyzed in MCF-10A acini by IF staining of Laminin V. (Scale bar, 20 μm.) (D)
MCF-10A cells, either MSCV-PIG or GPR161, were grown as 3D acini in 1:1
Matrigel/collagen for 14 d. Phase contrast was used to monitor acinar
morphology. (Scale bar, 10 μm.) (E) Western blot analysis was used to
measure E-cad levels from total MCF-10A cell lysates (TCLs) or those treated
with Con A. (F) IF analysis of E-cad localization in MDA-MB-361 cells, either
stably expressing an empty vector (MSCV-PIG) or GPR161. [Scale bar, 10 μm
and (Inset) 20 μm.] (G) IF analysis of E-cad localization in human tumors
expressing low or high levels of GPR161. [Scale bar, 20 μm and (Inset) 10 μm.]
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Fig. 5. GPR161 forms a protein complex with IQGAP1 and βArr2. (A)
Western blot analysis of IQGAP1 serine phosphorylation in MCF-10A and
MDA-MB-361 cells either stably expressing an empty vector (MSCV-PIG) or
GPR161. (B) Myc-IQGAP1 and GPR161-FLAG were transfected into 293T cells,
followed 48 h later by Myc-IP. Western blot analysis was used to detect Myc
and FLAG. (C) Myc-IQGAP1, GPR161-FLAG, HA-βArr1, and HA-βArr2 were
transfected into 293T cells, followed 48 h later by HA-IP. Western blot
analysis was used to detect Myc, FLAG, and HA. (D) GPR161 and IQGAP1
antibodies were conjugated to protein G–Sepharose beads, followed by in-
cubation with MDA-MB-361 and BT-474 cell lysates. Western blot analysis
was used to detect co-IP of endogenous IQGAP1, βArr2, and GPR161. (E)
Western blot analysis was used to detect knockdown of IQGAP1 in MDA-MB-
361 cells. (F) MTT assay was used to measure cell proliferation in MDA-MB-
361 cells (MSCV-PIG or GPR161) transfected with control or IQGAP1 siRNA.
*P < 0.05 for the difference between GPR161-expressing cells treated with
control or IQGAP1 siRNA using an unpaired t test. (G) Quantification of
transwell migration assay of MDA-MB-361 cells either stably expressing an
empty vector (MSCV-PIG) or GPR161 and transfected with control or IQGAP1
siRNA. *P < 0.05 for the difference between GPR161-expressing cells treated
with control or IQGAP1 siRNA using an unpaired t test. (H) Expression of
GPR161 and IQGAP1 was analyzed in 748 breast tumor samples. P values
were calculated with Fisher’s exact test.
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(Millipore), IQGAP1 (Santa Cruz), phospho-Serine (Abcam), HA (Covance),
myc (Cell Signaling), and Flag (Sigma).
Cell Culture and Transfection. Cells were cultured in the following medium:
MCF-10A [DMEM/F12, 5% (vol/vol) horse serum, epidermal growth factor (20
ng/mL), hydrocortisone (0.5 μg/mL), cholera toxin (100 ng/mL), insulin (10 μg/mL),
penicillin/streptomycin (P/S)], BT-474 [Improved Minimal Essential Medium, 10%
FBS, Insulin (10 μg/mL), P/S], MDA-MB-361 [DMEM, 15% FBS, L-Glutamine (5 mL),
nonessential amino acids (5 mL), P/S], BT-20 [DMEM, 15% (vol/vol) FBS, P/S],
MDA-MB-157 (DMEM, 10% FBS, P/S), MDA-MB-436 (DMEM, 10% FBS, P/S), and
293T (DMEM, 10% FBS, P/S). Cells were transfected by using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s suggested protocol. Retroviruses
expressing MSCV-PIG and GPR161 were prepared as described (30). GPR161 and
control shRNA were ordered from Thermo Scientific. The GPR161 sequences are
as follows: TCTTGTACAAGGTGACCAC and AGGACTTCTTGTACAAGGT. MCF-10A
cells were cultured in 3D as previously described (17). Control and IQGAP1 siRNA
were obtained from Sigma.
Cytosolic E-cad Assay. Samples were treated with Con A covalently linked to
Sepharose (Amersham). Confluent cells were washed with PBS and lysed in
radioimmunoprecipitation assay buffer (20 mM Tris·HCl, pH 7.4, 150 mM
NaCl, 5 mM EDTA, 1% Triton X-100) plus aprotinin, leupeptin, and sodium
orthovanadate. Lysates were rotated at 4 °C for 20 min and then centrifuged
for 20 min at 20,000 × g. A total of 1.25 mg of each sample was diluted in
500 μL RIPA buffer. A total of 50 μL of Con A–Sepharose was added to each
tube, which then were incubated at 4 °C for 1 h with rotation. After a brief
centrifugation, the supernatant was removed to a fresh microfuge tube,
25 mL of Con A–Sepharose was added, and the samples were rotated at 4 °C
for 1 h. After brief centrifugation, the supernatant was removed and sam-
ples were subjected to SDS/PAGE on 10% acrylamide gels.
Indirect Immunofluorescence. Cells grown on glass coverslips in 12-well plates
were fixed in 2% paraformaldehyde for 10 min, then washed three times in
PBS:glycine. Cells were permeabilized in 0.2% Triton X-100 for 10 min at 4 °C,
then washed three times with immunofluorescence wash, and blocked with
10% goat serum for 1 h. Unconjugated primary antibodies were incubated
in 10% goat serum for 2 h with gentle rocking, followed by three washes.
Secondary antibodies conjugated to Alexa Fluor dyes (Invitrogen) were
added for 1 h. Coverslips were then washed, incubated with DAPI for 5 min,
and then mounted on glass slides with Prolong (Molecular Probes).
The 3D acinar structures grown in eight-well chamber slides were washed
once in PBS, fixed in 5% formalin for 10 min, washed three times with PBS:
glycine, permeabilized with 0.5% Triton X-100, washed three times with PBS:
glycine, and then incubated in primary block (IF wash, 10% goat serum) for
1 h. Acini were incubated for 30 min in secondary block [IF wash, 10% goat
serum, F(ab’)2]. Antibodies were diluted in secondary block and incubated
for 2 h, followed by three washes with IF wash. Secondary antibodies were
diluted in primary block and incubated for 1 h, followed by two IF washes and
incubation with DAPI. Acini were mounted with Prolong. Tissue sections were
processed for immunofluorescence as previously described (31). All fluores-
cence images were collected using an Axiovert 200M equipped with an Apo-
tome imaging system. Images were analyzed using Axiovision software.
Proliferation Assay. Cells were seeded in 96-well plates (5,000 cells per well)
and allowed to grow for the indicated lengths of time. The MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) Cell Proliferation
Assay (ATCC) was used to monitor cell proliferation according to the man-
ufacturer’s suggested protocol.
Transwell Migration Assay. Cells were seeded in 24-well plates containing 8 μm
transwell migration filters, then fixed and stained with DAPI, and the mi-
grated cells quantified.
IP. Cells grown in 100 mm plates were lysed in a buffer composed of 50 mM
Tris·HCl, 150 mM NaCl, 10 mM NaF, 0.7% CHAPS, and protease inhibitors.
We incubated a 500 μg protein with 1 μg antibody and 25 μL Protein G
Sepharose beads (GE Healthcare) at 4 °C for 2 h with rotation. The beads were
washed twice in lysis buffer and the bound proteins eluted with sample buffer.
The samples were subjected to SDS/PAGE on 10% acrylamide gels.
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